

Attorney Docket No.:

KUZ0028US.NP

Inventors:

Tateishi et al.

Serial No.:

10/566,350

Filing Date:

January 27, 2006

Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (currently amended): An adhesive patch having a pressure-sensitive adhesive layer comprising ~~bisoprolol- and/or a pharmaceutically acceptable salt thereof~~ a pharmaceutically acceptable salt of bisoprolol, wherein said adhesive layer is a matrix type, and the composition thereof contains 2-ethylhexyl acrylate·vinyl acetate·acrylic acid copolymer, ~~a percutaneous absorption promoter selected from the group consisting of lauryl alcohol, myristyl alcohol, oleyl alcohol, isostearyl alcohol, diethyl sebacate, lauric acid diethanolamide, isopropyl myristate, glycerol monocaprate, glycerol monolaurate, glycerol monooleate, sorbitan monolaurate, propylene glycol monolaurate, polyoxyethylene lauryl ether, and pyrothiodecane, and an organic acid and/or a pharmaceutically acceptable salt thereof~~ sodium acetate, and the penetration rate of bisoprolol through skin is 4-300 $\mu\text{g}/\text{h}\cdot\text{cm}^2$.

Claims 2-4 (canceled)

Claim 5 (previously presented): The adhesive patch according to claim 1, wherein the composition of the pressure-sensitive adhesive layer contains further an elastmeric polymer.

Claim 6 (original): The adhesive patch according to claim 5, wherein the elastmeric polymer is at least one kind selected from a group consisting of styrene-isoprene-styrene block copolymer, polyisobutylene, isoprene rubber, styrene-

Attorney Docket No.: KUZ0028US.NP
Inventors: Tateishi et al.
Serial No.: 10/566,350
Filing Date: January 27, 2006
Page 3

butadine-styrene block copolymer, styrene-butadine rubber and silicone rubber.

Claims 7-10 (canceled)

Claim 11 (currently amended): The adhesive patch according to claim 1, wherein the ~~drug~~ pharmaceutically acceptable salt of bisoprolol is bisoprolol hemifumarate.

Claims 12-19 (canceled)

Claim 20 (previously presented): The adhesive patch according to claim 1, wherein the patch further comprises a backing contacting the pressure-sensitive adhesive layer.

Claim 21 (canceled)

Claim 22 (currently amended): The adhesive patch according to claim 1, wherein the penetration rate of bisoprolol through the skin is ~~about 34.0 to about 54.3~~ between 4 and 54.3 $\mu\text{g}/\text{h}\cdot\text{cm}^2$.

Claim 23 (currently amended): The adhesive patch according to ~~claim 8~~ claim 1, wherein the pressure-sensitive adhesive layer contains 0.1 to 10 wt % of ~~the organic acid and/or the pharmaceutically acceptable salt thereof~~ sodium acetate based on the weight of the total composition of pressure-sensitive adhesive layer.

Claim 24 (currently amended): The adhesive patch according to claim 23, wherein the pressure-sensitive

Attorney Docket No.: KU20028US.NP
Inventors: Tateishi et al.
Serial No.: 10/566,350
Filing Date: January 27, 2006
Page 4

adhesive layer contains 4.5 to 8.5 wt % of ~~the organic acid and/or the pharmaceutically acceptable salt thereof~~ sodium acetate based on the weight of the total composition of pressure-sensitive adhesive layer.

Claim 25 (currently amended): The adhesive patch according to ~~claim 9~~ claim 1, wherein the pressure-sensitive adhesive layer contains 0.1 to 20 wt % of isopropyl myristate based on the weight of the total composition of pressure-sensitive adhesive layer.

Claim 26 (currently amended): The adhesive patch according to claim 25, wherein the pressure-sensitive adhesive layer contains ~~5~~ 10 to 15 wt % of isopropyl myristate based on the weight of the total composition of pressure-sensitive adhesive layer.

Claim 27 (previously presented): The adhesive patch according to claim 6, wherein the elastmeric polymer is styrene-isoprene-styrene block copolymer or polyisobutylene.

Claim 28 (currently amended): The adhesive patch according to ~~claim 21~~ claim 22, wherein the pressure-sensitive adhesive layer contains 0.1 to 10 wt % of ~~the organic acid and/or the pharmaceutically acceptable salt thereof~~ sodium acetate and 0.1 to 20 wt % of isopropyl myristate based on the weight of the total composition of pressure-sensitive adhesive layer.

Claim 29 (currently amended): The adhesive patch according to claim 28, wherein the pressure-sensitive

Attorney Docket No.: **KUZ0028US.NP**
Inventors: **Tateishi et al.**
Serial No.: **10/566,350**
Filing Date: **January 27, 2006**
Page 5

adhesive layer contains 4.5 to 8.5 wt % of ~~the organic acid and/or the pharmaceutically acceptable salt thereof~~ sodium acetate and 5 to 15 wt% of isopropyl myristate based on the weight of the total composition of pressure-sensitive adhesive layer.

Claim 30 (previously presented): The adhesive patch according to claim 28, wherein the pressure-sensitive adhesive layer contains further an elastmeric polymer

selected from a group consisting of styrene-isoprene-styrene block copolymer, polyisobutylene, isoprene rubber, styrene-butadiene-styrene block copolymer, styrene-butadiene rubber and silicone rubber.

Claim 31 (previously presented): The adhesive patch according to claim 30, wherein the elastmeric polymer is styrene-isoprene-styrene block copolymer or polyisobutylene.